EXCLUSIVE: NICE decision means kids diagnosed with devastating neurodegenerative condition will no longer receive life-lengthening enzyme therapy on NHS ...
The Rich family have seen first hand how much the drug can help children with a devastating Batten disease diagnosis ...
Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), joins the global ...
Abstract: Batten disease (neuronal ceroid lipofuscinosis) is a rare pediatric neurodegenerative disorder whose early MRI signs are subtle and often missed. We propose TinyViT-Batten, a few-shot Vision ...
Copyright: © 2026 The Author(s). Published by Elsevier B.V. Zolgensma is injected intravenously, relying on the tropism of AAV9-SMN1 to the CNS and its ability to ...
NEW YORK – The US Food and Drug Administration has approved Latus Bio's investigational new drug application, allowing the firm to begin clinical trials of a gene therapy candidate in patients with ...
Latus Bio Inc. has reported IND clearance by the FDA for LTS-101, a gene therapy candidate to treat the CNS manifestations of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease. The ...
The National Institutes of Health awarded more than $8 million to the Kennedy Krieger Institute for researching rare disorders that negatively affect children.The money will establish a ...
Batten disease is a rare inherited condition that affects brain development and function. CLN3 disease is the most common type of this disease. The symptoms are life changing. They usually begin ...
EDEN PRAIRIE, MN / ACCESS Newswire / October 16, 2025 / Helen’s Pink Sky Foundation will take center stage at one of the world’s premier sporting events this fall, with its logo set to appear on BWT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results